James Stevenson

15.1k total citations · 2 hit papers
137 papers, 5.9k citations indexed

About

James Stevenson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, James Stevenson has authored 137 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in James Stevenson's work include Lung Cancer Treatments and Mutations (48 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Lung Cancer Diagnosis and Treatment (27 papers). James Stevenson is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Lung Cancer Diagnosis and Treatment (27 papers). James Stevenson collaborates with scholars based in United States, United Kingdom and Taiwan. James Stevenson's co-authors include Peter J. O’Dwyer, Corey J. Langer, Shirish M. Gadgeel, Stephen M. Hahn, Amita Patnaik, Matthew A. Gubens, Hossein Borghaei, Leena Gandhi, Lecia V. Sequist and Nathan A. Pennell and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

James Stevenson

129 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. profile →
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

2017 349 citations Monica Khunger, Sagar Rakshit et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Stevenson United States	38	3.5k	2.8k	1.2k	568	546	137	5.9k
Shadia I. Jalal United States	33	3.5k 1.0×	2.2k 0.8×	983 0.8×	642 1.1×	479 0.9×	134	4.9k
Charles Butts Canada	32	3.5k 1.0×	2.6k 0.9×	1.1k 0.9×	778 1.4×	356 0.7×	96	5.3k
Lizza Hendriks Netherlands	36	3.2k 0.9×	3.0k 1.1×	820 0.7×	420 0.7×	587 1.1×	221	5.1k
Gregory A. Masters United States	36	4.1k 1.1×	4.0k 1.4×	1.3k 1.1×	849 1.5×	841 1.5×	127	6.9k
Apar Kishor Ganti United States	37	2.5k 0.7×	1.9k 0.7×	1.8k 1.5×	356 0.6×	656 1.2×	262	5.5k
Kaoru Kubota Japan	44	4.4k 1.2×	3.7k 1.3×	1.5k 1.3×	486 0.9×	740 1.4×	269	7.1k
Purvish M. Parikh India	21	2.6k 0.7×	2.6k 0.9×	952 0.8×	278 0.5×	587 1.1×	160	4.4k
Jyoti D. Patel United States	38	3.9k 1.1×	3.4k 1.2×	1.4k 1.2×	495 0.9×	832 1.5×	230	6.1k
Alan B. Sandler United States	44	4.5k 1.3×	3.7k 1.3×	2.4k 2.0×	638 1.1×	1.0k 1.9×	109	7.5k
Thomas E. Stinchcombe United States	41	3.9k 1.1×	3.7k 1.3×	1.7k 1.4×	382 0.7×	824 1.5×	215	6.9k

Countries citing papers authored by James Stevenson

Since Specialization

Citations

This map shows the geographic impact of James Stevenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Stevenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Stevenson more than expected).

Fields of papers citing papers by James Stevenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Stevenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Stevenson. The network helps show where James Stevenson may publish in the future.

Co-authorship network of co-authors of James Stevenson

This figure shows the co-authorship network connecting the top 25 collaborators of James Stevenson. A scholar is included among the top collaborators of James Stevenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Stevenson. James Stevenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Rodney D., et al.. (2025). Synthesis of Psilocin, Psilocybin and 5‐MeO‐DMT Succinate, All Labelled With Carbon‐14 at the Indole 2‐Position. Journal of Labelled Compounds and Radiopharmaceuticals. 68(9-10). e4155–e4155.

Patel, Jyoti D., James Stevenson, Hui Chen, et al.. (2024). EP.12H.01 A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S657–S657. 2 indexed citations

Aggarwal, Charu, James Stevenson, Dariusz M. Kowalski, et al.. (2024). Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. Cancer Research. 84(7_Supplement). CT249–CT249. 1 indexed citations

Lee, Monica, Meera Patel, Hadil Zureigat, et al.. (2024). Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.. Journal of Clinical Oncology. 42(16_suppl). 8096–8096. 1 indexed citations

Delasos, Lukas, Wei Wei, Khaled A. Hassan, et al.. (2023). Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab. Clinical Lung Cancer. 24(6). e205–e213. 7 indexed citations

Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2021). OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). S8–S8. 1 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations

Gadgeel, Shirish M., Nathan A. Pennell, Mary J. Fidler, et al.. (2018). Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 13(9). 1393–1399. 155 indexed citations

Khunger, Monica, Prantesh Jain, Sagar Rakshit, et al.. (2018). Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer. 19(3). e335–e348. 45 indexed citations

10.

Argiris, Athanassios, Ju‐Whei Lee, James Stevenson, et al.. (2017). Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Annals of Oncology. 28(12). 3037–3043. 14 indexed citations

11.

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G. Journal of Thoracic Oncology. 12(1). S391–S392. 1 indexed citations

12.

Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations

13.

Sohal, Davendra, Brian I. Rini, Alok A. Khorana, et al.. (2015). Prospective Clinical Study of Precision Oncology in Solid Tumors. JNCI Journal of the National Cancer Institute. 108(3). 63 indexed citations

14.

Rengan, Ramesh, Rosemarie Mick, Daniel A. Pryma, et al.. (2012). A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. Journal of Thoracic Oncology. 7(4). 709–715. 59 indexed citations

15.

Midgley, Rachel, Rachel Kerr, Keith T. Flaherty, et al.. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology. 18(12). 2025–2029. 43 indexed citations

16.

Roberts, David W., Jonathan Schick, Susan R. Conway, et al.. (2005). Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. British Journal of Cancer. 92(6). 1149–1158. 121 indexed citations

17.

Machtay, Mitchell, Jason H. Lee, James Stevenson, et al.. (2004). Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response. Journal of Thoracic and Cardiovascular Surgery. 127(1). 108–113. 45 indexed citations

18.

Stevenson, James, et al.. (2004). Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. British Journal of Cancer. 91(2). 213–218. 6 indexed citations

19.

Flaherty, Keith T., et al.. (2004). A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemotherapy and Pharmacology. 53(5). 404–408. 12 indexed citations

20.

O’Dwyer, Peter J. & James Stevenson. (1998). Chemotherapy of advanced colorectal cancer. Cancer treatment and research. 98. 111–152. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact